Coherus BioSciences Inc. (CHRS) Fundamentals

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
SHARE INFORMATION
Market Cap$ 612,415,693
Shares Outstanding77,422,970
Float61,135,023
Percent Float78.96%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 326,551,000
Latest Fiscal EPS$ -3.85
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions516
Institutional Holdings Date2022-04-30
Institutional Bought Previous 3 Months7,079,816
Institutional Holdings Percent85.4%
Institutional Sold Previous 3 Months10,928,893
Insider Holdings Date2022-03-31
Insider Bought Previous 3 Months1,014,744
Insider Holdings Percent1.6
Insider Sold Previous 3 Months7,733
Insider Shares Owned1,244,471
TRADING INFO
52 Week High$ 19.32
52 Week Low$ 7.24
52 Week High Change$ -41.92
21 Day Moving Average$ 8.7271
21 Day Extended Moving Average$ 8.7882
50 Day Moving Average$ 10.7774
50 Day Extended Moving Average$ 10.2112
200 Day Moving Average$ 14.3309
200 Day Extended Moving Average$ 13.2371
10 Day Average Volume1,368,617
20 Day Average Volume1,146,602
30 Day Average Volume1,042,295
50 Day Average Volume953,951
Alpha-0.012666
Beta1.1941
Standard Deviation0.158751
R20.126771
7 Day Price Change$ 0.32
7 Day Percent Change4.22%
21 Day Price Change$ -1.52
21 Day Percent Change-16.12%
30 Day Price Change$ -2.47
30 Day Percent Change-23.8%
Month to Date Price Change$ -1.13
Month to Date Percent Change-12.5%
Quarter to Date Price Change$ -5.00
Quarter to Date Percent Change-38.73%
180 Day Price Change$ -10.60
180 Day Percent Change-57.27%
200 Day Price Change$ -8.82
200 Day Percent Change-52.72%
Year to Date Price Change$ -8.05
Year to Date Percent Change-50.44%

Coherus BioSciences Inc. (CHRS) Key Ratios

PROFITABILITY
EBIT Margin-60.6%
EBITDA Margin-59.5%
Pre-Tax Profit Margin0.0%
Profit Margin Count-70.62%
Gross Margin80.4%
Profit Margin TOT-70.62%
INCOME STATEMENTS
Revenue$ 303,632,000
Revenue Per Share$ 3.9217
Revenue (3 Years)$ 63.96
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book45.90
Total Debt To Equity34.30
Int Coverage-7.00
Current Ratio3.30
Leverage Ratio7.00
Quick Ratio2.90
Long Term Debt To Capital0.97
VALUATION MEASURES
PE Ratio-2.70
Enterprise Value$ 681,465,126
Price to Sales2.017
Price to Free Cash-6.10
PE High Last 5 Years19.20
Price To Book45.90
Price To Cash Flow20.10
PE Low Last 5 Years-2.70
Price to Tangible Book45.90
MANAGEMENT EFFECTIVENESS
Receivables Turnover2.30
Invoice Turnover1.40
Assets Turnover0.40
Return Assets-33.69
Return on Equity-315.86
Return on Capital-37.23

Coherus BioSciences Inc. (CHRS) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEODennis M. Lanfear
Emplyoees332
Last AuditUQ
CIK0001512762
IndustryBiotechnology
SectorHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)(541714)
CONTACT INFO
Address333 Twin Dolphin Drive
Suite 600
Redwood City, CA 94065
Websitehttp://www.coherus.com
Facsimile-
Telephone+1 650 649-3530
Emaildarrington@coherus.com


Your Recent History
NASDAQ
CHRS
Coherus Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.